Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.

Alrajhi AM, Alshehri B, Alshahrani WA, AlHaj Issa A, Alotaibi AH, Abumustafa A, Alyousif G, Alkhudair N, Alalawi M, Alsuhebany N, Alzahrani M, Alghamdi A, Vishwakarma R, Bakr A, AlHaj Issa Z, Alateeq A, Alenazi AA, Alaboud MS, Alayaf B, As Sobeai HM, Al Sulaiman K

Open source

DOI: 10.1080/16078454.2026.2700811
Published: 2026 Dec 31
Container: Hematology (Amsterdam, Netherlands)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/16078454.2026.2700811,
  title = {Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.},
  author = {Alrajhi AM and Alshehri B and Alshahrani WA and AlHaj Issa A and Alotaibi AH and Abumustafa A and Alyousif G and Alkhudair N and Alalawi M and Alsuhebany N and Alzahrani M and Alghamdi A and Vishwakarma R and Bakr A and AlHaj Issa Z and Alateeq A and Alenazi AA and Alaboud MS and Alayaf B and As Sobeai HM and Al Sulaiman K},
  year = {2026},
  journal = {Hematology (Amsterdam, Netherlands)},
  doi = {10.1080/16078454.2026.2700811},
  url = {https://doi.org/10.1080/16078454.2026.2700811}
}

RIS

TY  - JOUR
TI  - Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
AU  - Alrajhi AM
AU  - Alshehri B
AU  - Alshahrani WA
AU  - AlHaj Issa A
AU  - Alotaibi AH
AU  - Abumustafa A
AU  - Alyousif G
AU  - Alkhudair N
AU  - Alalawi M
AU  - Alsuhebany N
AU  - Alzahrani M
AU  - Alghamdi A
AU  - Vishwakarma R
AU  - Bakr A
AU  - AlHaj Issa Z
AU  - Alateeq A
AU  - Alenazi AA
AU  - Alaboud MS
AU  - Alayaf B
AU  - As Sobeai HM
AU  - Al Sulaiman K
PY  - 2026
JO  - Hematology (Amsterdam, Netherlands)
DO  - 10.1080/16078454.2026.2700811
UR  - https://doi.org/10.1080/16078454.2026.2700811
ER  -

APA

AM, A., B, A., WA, A., A, A. I., AH, A., A, A., G, A., N, A., M, A., N, A., M, A., A, A., R, V., A, B., Z, A. I., A, A., AA, A., MS, A., B, A., HM, A. S., & K, A. S. (2026). Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.. Hematology (Amsterdam, Netherlands). https://doi.org/10.1080/16078454.2026.2700811

Source records

pubmed · retrieved 2026-09-25T22:53:18.936Z